Thursday, December 2, 2010

MedImmune's Oncology Portfolio Advances

MedImmune,the biologics business of British pharma titan AstraZeneca,is perhaps best known for its FluMist product,but it is also quite active in oncology innovation.They are using insights and understanding of cancer to discover breakthrough biologic therapies that can be used to treat specific cancers for the individual patient,according to Jerry McMahon,PhD,Senior Vice President and Oncology Innovative Medicines Unit Leader.
MedImmune's pipeline is focused on eliminating cancer cells in more effective and targeted ways.They are currently researching their products MEDI-575,an antibody with promise in treatment of solid tumors;and the immunotoxin moxetamomab pasudotox(CAT 8015),which is being evaluated for therapeutic potential against certain leukemias.
These are early phase studies,but MedImmune is excited about the oncology portfolio's progress and looks forward to advancing oncology products into expanded clinical studies in the near future,Dr.McMahon indicated.
MedImmune,based in Gaithersburg,Maryland,employs about 3500 people worldwide.Jerry McMahon,who assumed his position in October,received a doctorate in Biochemistry and Genetics from Rensselaer Polytechnic Institute in Troy,New York.
AstraZeneca(AZN)

No comments: